Arca
Skip to content
Tools
Tools

TYMS: Thymidylate synthase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the reductive methylation of 2'-deoxyuridine 5'- monophosphate (dUMP) to thymidine 5'-monophosphate (dTMP), using the cosubstrate, 5,10- methylenetetrahydrofolate (CH2H4folate) as a 1- carbon donor and reductant and contributes to the mitochondrial and nuclear de novo thymidylate biosynthesis pathway. {ECO:0000269|PubMed:11278511, ECO:0000269|PubMed:21876188, ECO:0000269|PubMed:22235121}.

  • Drugs that act on it: 9
  • Approved: 6
  • In phases 1 to 3: 3
  • Sponsors: 7

Who Is On It, and How Far Along

Every drug ChEMBL records acting on TYMS, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved6

  • Fluorouracil
  • Capecitabine
  • Pemetrexed
  • Tegafur
  • Raltitrexed
  • Floxuridine

Phase 32

  • Doxifluridine
  • Nolatrexed

Phase 21

  • OSI-7904

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Eximias Pharmaceutical111%
    • Hansoh BioMedical R&D Company111%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule9100%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 8 of 9 act as: Thymidylate synthase inhibitor; the rest name their own mechanism.
    FluorouracilApprovedSpectrum PharmaceuticalsSmall moleculeInhibitor—1,281—
    CapecitabineApprovedCheplapharmSmall moleculeInhibitor—874Boxed warning
    PemetrexedApprovedHansoh BioMedical R&D CompanySmall moleculeInhibitor—520—
    TegafurApprovedOno PharmaceuticalSmall moleculeInhibitor—72—
    RaltitrexedApproved—Small moleculeInhibitor—15—
    FloxuridineApprovedPfizerSmall moleculeInhibitor—14Boxed warning
    DoxifluridinePhase 3—Small moleculeInhibitor—0—
    NolatrexedPhase 3Eximias PharmaceuticalSmall moleculeAntagonistThymidylate synthase antagonist0—
    OSI-7904Phase 2Astellas PharmaSmall moleculeInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 43 in all, from ClinicalTrials.gov.
    HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric CancerCapecitabinePhase 2Not yet recruitingShanghai Zhongshan Hospital2026-11-17
    Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5CapecitabinePhase 3Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2026-11-17
    Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal CancerFluorouracilPhase 2Not yet recruitingDamanhour University2026-11-17
    Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung CancerPemetrexedPhase 3Not yet recruitingGoethe University2026-11-17
    RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaCapecitabine, FluorouracilPhase 2 / Phase 3Not yet recruitingRemeGen Co., Ltd.2026-11-13
    Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung CancerPemetrexedPhase 2Not yet recruitingGuizhou Medical University2026-11-13
    SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)Capecitabine, FluorouracilPhase 3Not yet recruitingFudan University2026-11-12
    QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma PatientsFluorouracilPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2026-11-12
    Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaTegafurPhase 2RecruitingBeijing Tsinghua Chang Gung Hospital2026-11-12
    Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast CancerCapecitabine, Fluorouracil—Active, not recruitingPeking Union Medical College Hospital2026-11-09
    GK01 Cell Therapy in Gastric Cancer With Peritoneal MetastasisTegafurPhase 1Not yet recruitingRuijin Hospital2026-11-06
    A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung CancerPemetrexedPhase 2Not yet recruitingTang-Du Hospital2026-11-05
    Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal CancerCapecitabine, FluorouracilPhase 3Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.2026-11-04
    Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract CancerCapecitabine, FluorouracilPhase 3Not yet recruitingZhai Wenlong2026-11-04
    A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerFluorouracilPhase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.2026-11-04
    Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III TrialPemetrexedPhase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris2026-11-04
    Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II TrialCapecitabinePhase 1 / Phase 2Not yet recruitingXuelei Ma MD2026-11-03
    A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung CancerPemetrexedPhase 1Not yet recruitingHansoh BioMedical R&D Company2026-10-27
    ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCPemetrexedPhase 3Not yet recruitingJiangsu Aosaikang Pharmaceutical Co., Ltd.2026-10-27
    Clinical and Radiographic Evaluation of Dia-Root Bio MTA for Indirect Pulp Capping in Young Permanent MolarsPemetrexedNot applicableRecruitingTanta University2026-10-26
    A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerPemetrexedPhase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2026-10-26
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyTegafurPhase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2026-10-14
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerTegafurPhase 2RecruitingRuijin Hospital2026-10-09
    Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal AdenocarcinomaFloxuridine—RecruitingAdventHealth2026-09-29
    CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP TrialFloxuridinePhase 1Not yet recruitingCity of Hope Medical Center2026-09-25
    A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaTegafurPhase 2Not yet recruitingThe First Affiliated Hospital of Zhengzhou University2026-09-18
    A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaTegafurPhase 3Not yet recruitingOno Pharmaceutical Co., Ltd.2026-09-14
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.TegafurPhase 2RecruitingXijing Hospital2026-08-26
    Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction AdenocarcinomaTegafurPhase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University2026-08-19
    Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver MetastasisFloxuridinePhase 2RecruitingSunnybrook Health Sciences Centre2026-08-14
    Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular CarcinomaRaltitrexedEarly phase 1Active, not recruitingNanfang Hospital, Southern Medical University2026-08-05
    Effects of HIPEC on Postoperative Bowel Motility and ComplicationsRaltitrexed—Active, not recruitingPeking University People's Hospital2026-01-20
    A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal CancerRaltitrexedPhase 1RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2026-01-16
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRaltitrexedPhase 2RecruitingNanfang Hospital, Southern Medical University2026-01-08
    Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyFloxuridinePhase 2RecruitingMichael J Cavnar, MD2025-10-01
    Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by SurgeryFloxuridinePhase 2RecruitingErasmus Medical Center2025-03-21
    Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic TherapyFloxuridinePhase 3RecruitingThe Netherlands Cancer Institute2025-03-04
    Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1,Chemotherapy and Target Therapy for Metastatic Colorectal CancerRaltitrexedPhase 2RecruitingFudan University2025-02-24
    A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAICRaltitrexed—Not yet recruitingXuhua Duan2025-02-12
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRaltitrexedPhase 2RecruitingFudan University2025-02-06
    CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRCRaltitrexedPhase 2Not yet recruitingFudan University2024-10-30
    HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)FloxuridinePhase 2RecruitingOslo University Hospital2024-03-15
    Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialFloxuridinePhase 3RecruitingECOG-ACRIN Cancer Research Group2023-05-17

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Dyskeratosis congenita, digenic
    0.66
    Non-small cell lung carcinoma
    0.63
    Colonic neoplasm
    0.60
    Neoplasm
    0.60
    Dyskeratosis congenita
    0.60
    Breast carcinoma
    0.60
    Gastric neoplasm
    0.58
    Malignant colon neoplasm
    0.56

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1952, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P04818, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.